Petros Pharmaceuticals (PTPI) Competitors $0.03 +0.00 (+0.29%) As of 07/3/2025 12:13 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. CANF, THAR, ONVO, GENE, SPRC, NBY, EVAX, PRFX, ARTL, and APVOShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Can-Fite BioPharma (CANF), Tharimmune (THAR), Organovo (ONVO), Genetic Technologies (GENE), SciSparc (SPRC), NovaBay Pharmaceuticals (NBY), Evaxion A/S (EVAX), PainReform (PRFX), Artelo Biosciences (ARTL), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Can-Fite BioPharma Tharimmune Organovo Genetic Technologies SciSparc NovaBay Pharmaceuticals Evaxion A/S PainReform Artelo Biosciences Aptevo Therapeutics Can-Fite BioPharma (NYSE:CANF) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Which has higher earnings and valuation, CANF or PTPI? Can-Fite BioPharma has higher earnings, but lower revenue than Petros Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.36-$7.63M-$1.79-0.57Petros Pharmaceuticals$5.11M0.21-$8.16M-$119.000.00 Do analysts prefer CANF or PTPI? Can-Fite BioPharma currently has a consensus price target of $14.00, indicating a potential upside of 1,272.55%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CANF or PTPI more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Petros Pharmaceuticals N/A -78.22%-23.50% Do institutionals & insiders believe in CANF or PTPI? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, CANF or PTPI? Can-Fite BioPharma has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Does the media refer more to CANF or PTPI? In the previous week, Can-Fite BioPharma had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Petros Pharmaceuticals. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Can-Fite BioPharma Neutral Petros Pharmaceuticals Neutral SummaryCan-Fite BioPharma beats Petros Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.09M$790.73M$5.50B$9.01BDividend YieldN/A4.84%5.38%4.04%P/E Ratio-0.011.3527.6020.30Price / Sales0.21226.97369.38103.94Price / CashN/A23.4436.6357.47Price / Book0.016.298.055.68Net Income-$8.16M-$27.73M$3.18B$249.13M7 Day PerformanceN/A1.21%2.82%3.30%1 Month PerformanceN/A9.47%3.70%5.20%1 Year PerformanceN/A7.77%35.41%21.38% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.6756 of 5 stars$0.03+0.3%N/A-99.7%$1.09M$5.11M-0.0120Gap DownCANFCan-Fite BioPharma2.7515 of 5 stars$1.05-0.9%$14.00+1,239.7%-57.9%$3.70M$674K-0.588Gap UpTHARTharimmune3.3811 of 5 stars$1.31-2.2%$17.00+1,197.7%-44.7%$3.57MN/A-0.172ONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpGENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050High Trading VolumeSPRCSciSparc0.2517 of 5 stars$0.30+1.4%N/A-59.4%$3.32M$1.31M0.004Stock SplitNBYNovaBay Pharmaceuticals2.0787 of 5 stars$0.57flat$0.85+49.1%-71.0%$3.32M$9.78M-0.0130EVAXEvaxion A/S2.847 of 5 stars$2.44+5.2%$10.00+309.8%-84.9%$3.25M$3.34M-2.1060PRFXPainReform0.773 of 5 stars$1.46-9.0%$8.00+447.9%-21.9%$3.23MN/A-0.014ARTLArtelo Biosciences3.0196 of 5 stars$5.88+1.9%$33.00+461.2%+32.3%$3.16MN/A-0.335Gap UpAPVOAptevo Therapeutics2.1603 of 5 stars$3.25-22.1%$219,040.00+6,739,592.3%-100.0%$3.15M$3.11M0.0050High Trading Volume Related Companies and Tools Related Companies Can-Fite BioPharma Competitors Tharimmune Competitors Organovo Competitors Genetic Technologies Competitors SciSparc Competitors NovaBay Pharmaceuticals Competitors Evaxion A/S Competitors PainReform Competitors Artelo Biosciences Competitors Aptevo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
